Posted on

dementia seeds

Our aim is to demonstrate that the OM, collected from individuals at early stages of dementia, contains disease-specific pathological proteins that can be used to set up a diagnostic test which will help to discriminate between AD, LBD and FTD-tau.

Olfactory mucosa samples, collected from a well-characterized group of individuals with AD, LBD and FTD-tau, will be analyzed using an ultrasensitive test (RT-QuIC) that can detect the presence of a trace amount of specific pathological proteins, otherwise undetectable using conventional tests. Detection and identification of these proteins will allow us to identify the type of dementia at early stages when symptoms are not specific and might overlap. Results will be correlated with clinical, biochemical, neuropathological and MRI data.

Impact on Diagnosis/Treatment of Parkinson’s Disease:

Next Steps for Development:

Co-Applicant Dr Liz Sampson, MCPCRD UCL, leads Work stream 1 (WS1).

In order to provide a strong theoretical and practical foundation for the development of the ICP, Workstream 1 (WS1) led by Dr Liz Sampson, will (i) map the evidence base for existing end of life care guidance and/or pathways in dementia, (ii) update recent comprehensive reviews of quality indicators in end of life and palliative care, and psychometric properties of instruments to measure end of life care in dementia, and (iii) identify existing UK services in end of life care in dementia and map national “best practice” sites. An initial “broad sweep” survey of UK services will lead to an in-depth service evaluation of selected services to inform the development of the ICP.

Amador S, Sampson EL, Goodman C & Robinson L (in preparation) Quality indicators for palliative care: How useful are they for the assessment of end-of-life care in dementia? BMJ Quality and Safety

The Supporting Excellence in End of Life Care in Dementia (SEED) programme aims to support professionals, both commissioners and providers, to deliver good quality, community-based end of life and palliative care in dementia, through the development of an Integrated Care Pathway (ICP). Led by the University of Newcastle, in collaboration with partner organisations including University College London, the University of Hertfordshire and the National Council of Palliative Care.